Inactive Instrument

All News Palatin Technologies, Inc. Nyse

Equities

PTN

US6960773041

End-of-day quote Nyse Other stock markets
- ^USD	-

15/05	Transcript : Palatin Technologies, Inc., Q3 2024 Earnings Call, May 15, 2024
15/05	Palatin Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update	16/05	AQ
Transcript : Palatin Technologies, Inc., Q3 2024 Earnings Call, May 15, 2024	15/05
Palatin Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15/05	CI
Palatin to Report Third Quarter Fiscal Year 2024 Results, Teleconference and Webcast to be held on May 15, 2024	10/05	AQ
Transcript : Palatin Technologies, Inc. - Special Call	08/05
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity	03/05	AQ
Palatin to Host Virtual KOL Event 'Beyond GLPs, the Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance' on May 8, 2024	01/05	AQ
PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024	09/04	AQ
Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	08/04	CI
PALATIN ANNOUNCES RESULTS OF PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	29/02	AQ
Sector Update: Health Care Stocks Decline Late Afternoon	29/02	MT
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial	29/02	MT
Transcript : Palatin Technologies, Inc. - Special Call	28/02
Transcript : Palatin Technologies, Inc., Q2 2024 Operating Results Call, Feb 15, 2024	15/02
Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	15/02	CI
PALATIN ANNOUNCES DATABASE LOCK FOR PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	06/02	AQ
Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease	05/02	CI
PALATIN ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING	31/01	AQ
PALATIN PROVIDES CORPORATE UPDATE AND HIGHLIGHTS STRATEGIC PRIORITIES FOR CALENDAR YEAR 2024	09/01	AQ
Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024	08/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Palatin Technologies, Inc. Nyse

Equities

PTN

US6960773041

All News

Filters